定向分支桥接支架选择对美国主动脉研究联盟开窗分支腔内主动脉修复靶动脉结局的影响
本研究分析美国9项前瞻性医生发起的研究器械豁免研究中2005至2020年800例患者2426条肾-肠系膜动脉的靶动脉结局,比较自膨式支架(SESG)、球囊扩张式支架(BESG)和混合支架组合(HSG)对靶动脉通畅性及免于不稳定、内漏和再干预的影响。结果显示BESG组靶动脉免于不稳定、内漏和再干预的比例显著低于SESG和HSG组,但通畅性无差异,BESG的性能劣势主要由iCAST使用驱动。
要点
- BESG组5年免于靶动脉不稳定、内漏和再干预的比例显著低于SESG和HSG组。
- 肾动脉和肠系膜动脉亚组中BESG的免于内漏和再干预均较低,但通畅性无差异。
- iCAST BESG与靶动脉不稳定最低相关,主要因内漏率较高。
核心结论
- 使用BESG的定向分支相比SESG和HSG具有更低的免于靶动脉不稳定、靶动脉内漏和靶动脉再干预率。
- 定向分支的通畅性不受支架构建类型影响。
- BESG相关的性能劣势似乎主要由iCAST的使用驱动。
研究设计与样本
- 分析美国9项前瞻性医生发起的研究器械豁免研究中2005至2020年入组患者。
- 纳入至少一条靶动脉通过定向分支使用SESG、BESG或HSG重建的患者。
- 共800例患者2426条肾-肠系膜动脉被定向分支重建。
主要发现
- 定向分支支架选择为SESG 1205条靶动脉(50%)、BESG 1095条(45%)、HSG 126条(5%)。
- SESG主要用于研究期的前三个四分位数,而BESG在2017至2020年间占所有支架的75%。
- 中位随访15个月(四分位距6-35个月)。
- 5年时,BESG组相比SESG组和HSG组分别具有更低的免于靶动脉不稳定率(78%±4% vs 88%±1% vs 96%±2%;log-rank P=.010)、免于靶动脉内漏率(87%±3% vs 97%±1% vs 99%±1%;log-rank P<.001)和免于靶动脉再干预率(83%±4% vs 95%±1% vs 99%±2%;log-rank P<.001)。
- 肾动脉亚组中,BESG、SESG和HSG的免于靶动脉不稳定无差异;但BESG靶向的肾动脉免于内漏和再干预率低于SESG和HSG(免于内漏:83%±6% vs 98%±1% vs 100%;log-rank P<.001;免于再干预:70%±10% vs 92%±1% vs 96%±4%;log-rank P=.022)。
临床怎么用
- 作者结论认为使用BESG的定向分支相比SESG和HSG具有更低的免于靶动脉不稳定、内漏和再干预率,且通畅性不受支架类型影响,该性能劣势似乎主要由iCAST使用驱动。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The purpose of this study was to evaluate the effect of directional branches (DBs) bridging stent choice on target artery (TA) outcomes during fenestrated-branched endovascular repair of complex abdominal and thoracoabdominal aortic aneurysms. METHODS: Patients enrolled in nine prospective physician-sponsored investigational device exemption studies in the United States between 2005 and 2020 were analyzed. All patients who had at least one TA incorporated by DB using either self-expandable (SESGs), balloon-expandable (BESGs), or hybrid stent graft combinations (HSGs). Endpoints were TA patency and freedom from TA endoleak, instability, and reintervention. RESULTS: There were 800 patients with 2426 renal-mesenteric arteries incorporated by DBs. DB stent selection was SESGs in 1205 TAs (50%), BESGs in 1095 TAs (45%), and HSGs in 126 TAs (5%). SESGs were predominantly used in the first three quartiles of the study period, whereas BESGs comprised 75% of all stents between 2017 and 2020. The median follow-up was 15 months (interquartile range, 6-35 months). At 5 years, BESGs had significantly lower freedom from TA instability (78% ± 4% vs 88% ± 1% vs 96% ± 2%; log-rank P =.010), freedom from TA endoleaks (87% ± 3% vs 97% ± 1% vs 99% ± 1%; log-rank P < .001), and freedom from TA reintervention (83% ± 4% vs 95% ± 1% vs 99% ± 2%; log-rank P <.001) compared with SESGs or HSGs, respectively. For renal arteries, there was no difference in freedom from TA instability for BESGs, SESGs, or HSGs. However, freedom from TA endoleaks and reintervention were lower for renal arteries targeted by BESGs compared with DBs targeted by SESGs and HSGs (83% ± 6% vs 98% ± 1% vs 100%; log-rank P < .001; and 70% ± 10% vs 92% ± 1% vs 96% ± 4%; log-rank P = .022). For mesenteric arteries, DBs targeted by BESGs had lower freedom from TA instability, endoleak, and reintervention than SESGs or HSGs. In stent-specific analysis, iCAST BESGs had the lowest freedom from TA instability either for renal or mesenteric arteries, primarily due to higher rates of TA endoleaks. There was no difference in patency in any scenario. Independent predictors of TA instability were age (+1-year: hazard ratio [HR], 0.97; 95% confidence interval [CI], 0.94-0.99), stent diameter (+1 mm: HR, 0.67; 95% CI, 0.57-0.80), and BESG (HR, 1.8; 95% CI, 1.1-2.9). CONCLUSIONS: DBs incorporated using BESGs had lower freedom from TA instability, TA endoleak, and TA reintervention compared with SESGs and HSGs. The patency of DBs was not affected by the type of stent construction. The observed performance disadvantage associated with BESGs appears to have largely been driven by iCAST usage.
引用
- Tenorio ER, Schanzer A, Timaran CH, et al. Effect of bridging stent graft selection for directional branches on target artery outcomes of fenestrated-branched endovascular aortic repair in the United States Aortic Research Consortium. J Vasc Surg. 2023. PMID: 36948277. doi:10.1016/j.jvs.2023.03.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。